GlassScriptPhysician profile
Laura Grace Asher
NPI 1346404852
$1,361.03
in general payments reported to CMS, 2019-2025
20 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.14 · 2020: $13.59 · 2021: $59.66 · 2022: $86.81 · 2023: $482 · 2024: $402 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $240.31 | 2023-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $163.95 | 2019-2024 | Rexulti, Abilify Maintena |
| Abbvie INC. | $137.66 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Lundbeck LLC | $112.42 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $110.17 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.36 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $79.49 | 2019-2025 | Breztri |
| Indivior INC. | $70.95 | 2019-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $35.28 | 2024-2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $35.03 | 2024-2025 | Mounjaro |
| Braeburn INC. | $29.69 | 2023-2024 | Brixadi |
| Amgen INC. | $20.68 | 2023 | Repatha |
| Sunovion Pharmaceuticals INC. | $20.13 | 2021 | |
| Gilead Sciences, INC. | $19.33 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $18.75 | 2023 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $18.59 | 2024 | Uzedy |
| Glaxosmithkline, LLC. | $16.86 | 2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $13.59 | 2020 | |
| Novo Nordisk INC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.